AU2005291856B2 - Antibody production method - Google Patents

Description

WO 2006/037182 PCT/AU2005/001540 "Antibody Production Method" Field of the Invention The present invention relates to a method for inducing a sustained production of antibodies or immunoglobulins. More particularly, it relates to a method of 5 inducing a sustained production of antibodies in the milk of a mammal. Background Art The advantage of producing antibodies in milk over the traditional source of antibodies from blood lies in the constancy of supply through the daily access to milk. After blood products are harvested, the production animal is allowed to 10 recover for extended periods (for example, up to one month). Hence, the yield of antibodies is limited (approximately 3 to 30 mg per month) due to the finite amount of blood that can be obtained. In contrast, for example, dairy animals milked daily results in significant increases in yield (eg 2 mg per day multiplied by 30 days, gives 150 mg per month). 15 Injections or infusions directly into the teat of the mammal have previously been used to stimulate the production of antibodies in milk. Such examples are set out in the following literature: J.L. Smith, J.S Hogan & K.L Smith (1999) "Efficacy of intramammary immunization with an Escherichia coli JS bacteria." Journal of Dairy Science, 82:2582-2588; J.S Hogan, K.L Smith, P.Schoenberger, S. Romig 20 & L Thompson (1997) "Response of antibody titres to intramammary immunization with Escherichia coli JS bacteria." Journal of Dairy Science, 80: 2398-2402; F.J Bourne, T.J Newby & J.W Chidlow (1975) "The influence of route of vaccination on the systemic and local immune response in the pig." Research in Veterinary Science, 18:244-248. Such injections are time consuming as they must be 25 repeated to re-stimulate antibody production. Furthermore, injection directly into the teat of a mammal frequently results in infections such as mastitis. Intramammary immunisation techniques have generally not been preferred as a route for vaccination under field conditions due to the high chance of mammary WO 2006/037182 PCT/AU2005/001540 -2 infection (R. F. Sheldrake (1987) Australian Journal of Dairy Technology, 42:30 32) and often requires application by highly skilled practitioners. It should be noted that much of the published literature concerning 5 immunoglobulin production in mammary gland secretions is directed to disease prevention (that is, vaccination) in animals or their offspring. Few are directed to the production of immunoglobulin enriched milk for the purposes of obtaining the immunoglobulins themselves. Summary of the Invention 10 In a first aspect of the invention, there is provided a method for inducing the sustained release of antibodies in milk comprising the step of: implanting at least one antigen releasing device adjacent to or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody 15 secretion into a mammary gland. According to a second aspect the invention also provides antibodies produced by any one of the methods of the present invention. According to a third aspect the present invention relates to a method for the production of milk containing antibodies which method comprises induction of 20 antibodies according to the method detailed above and then collecting the antibody containing milk from the mammal. The collection of milk may be effected using normal milking processes. Other objects, features, and advantages of the instant invention, in its details as seen from the above, and from the following description of the preferred 25 embodiment.

WO 2006/037182 PCT/AU2005/001540 -3 Brief Description of the Drawings Figure 1 shows a photograph of the supramammary gland stained blue due to migration of dye inoculated in the groin area of the animal (photo courtesy of Dr Martin CAKE, Anatomy Department Murdoch University). 5 Figure 2 shows a photograph of the intranasal immunisation of a goat. Figure 3 shows a photograph of the implantation of an antigen releasing device in accordance with an aspect of the present invention into the groin of a sheep. Figure 4 shows the location of the implanted antigen releasing device of Figure 3 in the sheep. 10 Figure 5 shows a schematic diagram of the apparatus used to implant the antigen releasing device. Figure 6 shows a photograph of the diffusion of a lipase protein from an antigen releasing device in accordance with an aspect of the present invention into a milk agar plate. As the enzyme diffuses from the pores of the tube, it hydrolyses the 15 lipids in the milk agar, as evident from the dark zones around the rod. The lipase protein was used as the model antigen for the development of the invention. Figure 7 shows a graph of the level of anti-lipase antibodies in milk from goats immunised with different protocols. The level of anti-lipase antibodies in milk from goats immunised with different protocols. The mean absorbance values of two 20 animals were plotted over 28 days for each protocol. Maximum antibody levels were achieved with the procedure using an antigen releasing device (CRD) and intramuscular injection. Figure 8 shows a graph of the individual absorbance levels of anti-lipase antibodies in two separate animals implanted with an antigen releasing device 25 (ARD) and given intramuscular injections. The levels of anti-lipase antibodies in two separate animals implanted with an antigen releasing device (CRD) and given WO 2006/037182 PCT/AU2005/001540 -4 intramuscular injections. The two results highlight the reproducible nature of the immunisation procedure Figure 9 shows a graph of the level of anti-lipase antibodies in serum from goats immunised with different protocols. The mean absorbance values of two animals 5 were plotted over 28 days for each protocol. Figure 10 shows a comparison of mean anti-lipase anti-body levels in milk (+) and serum (m) produced by immunisation of goats with an antigen releasing device (ARD) and intramuscular injection. Figure 11 shows a graph of anti-lipase antibody production in milk (+) and serum 10 (m) in goats implanted with an antigen releasing devices. The level of anti-lipase antibody levels in milk and the absence of anti-lipase antibodies in serum suggest that the antigens in the antigen releasing device implanted in the groin area are diffusing into the supramammary lymph node. Figure 12 shows photographs of a diffusion assay of milk agar on glass slides 15 illustrating the inhibitory effects of anti-lipase antibodies on the lipolytic activity of the lipase enzyme. Slide 1: PBS or saline was added to the wells. Slide 2: 5mg/ml lipase from P. fluorescens. Slide 3: 5mg/ml of lipase with an antibody negative serum (1:1 dilution). Slide 4: 5mg/ml of lipase with serum that was positive for anti-lipase antibodies (1:1 dilution). 20 Figure 13 shows a graph of the levels of IgG, IgA and IgM in the milk of goats inoculated with lipase from Pseudomonas fluorescens. Two groups of animals were inoculated in different locations (Group 1 (G1) into the flank and Group 2 (G2) in the region adjacent to the supramammary lymph nodes) on Days 0, 10 and 19. The relative levels of IgG, IgA and IgM were determined by ELISA. The 25 levels of all three classes of immunoglobulins were higher in the milk of Group 2 animals when compared to Group 1 animals.

- 5/1 Disclosure of the Invention General Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. 5 It is to be understood that the invention includes all such variation and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features. 10 Each document, reference, patent application or patent cited in this text is expressly incorporated herein by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness. 15 Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general knowledge or was known in Australia or any other country. The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. 20 Functionally equivalent products, compositions and methods are clearly within the scope of the invention as described herein. Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion 25 of any other integer or group of integers.

- 5/2 Through this specification the acronyms CRD and ARD are used interchangeably. Both refer to the antigen releasing device described, disclosed and claimed herein. Other definitions for selected terms used herein may be found within the 5 description of the invention and apply throughout. Unless otherwise defined, all WO 2006/037182 PCT/AU2005/001540 -6 other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs. Detailed Disclosure of the invention 5 This invention is based on the unexpected discovery that a sustained release of antibodies in milk can be achieved by stimulating the supramammary lymph node over a long period with antigen released from an implanted antigen releasing device implanted adjacent to, within close proximity of or within the supramammary gland. The advantage of stimulating the supramammary lymph 10 node lies in the proximity of the node to the mammary glands. Antibodies produced by the supramammary lymph node are secreted into the mammary glands and therefore enter the milk of the mammal. The present method causes stimulation of antibody production that can be maintained over long periods by the slow release of antigen from the antigen releasing device. The method stimulates 15 the production of different subclasses or isotypes of immunoglobulin, such as IgA, IgG and lgM. Thus, in a first aspect of the invention, there is provided a method for inducing the sustained release of antibodies in milk comprising the step of: implanting at least one antigen releasing device adjacent to, within close proximity of or within at 20 least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland. According to this invention the distance of the implant from the supramammary gland should be at least close enough that the release of antigen from the antigen 25 releasing device causes the antibody response of the mammal (into which it is implanted) to be maintained at a level that facilitates the production of antibodies in milk at levels that are therapeutically or anti-microbially suitable. For examples, the ARD may be implanted in the udder. Alternatively, by way of illustration the antigen releasing device is preferably implanted at a distance of up to 100 mm 30 from at least one supramammary lymph node, wherein in use the antigen WO 2006/037182 PCT/AU2005/001540 -7 releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland. Preferably, the antigen releasing device is implanted adjacent to or at a distance of between about 1 mm and 100 mm from the supramammary lymph 5 node. Most preferably, the distance is between about 50 mm and 100 mm. It will be appreciated that the present invention may be used to stimulate antibody production in a number of glands in an animal. In this respect immunisation at one gland has been shown to result in antibody activity in secretions by other mammary glands (see, for example, F.J Bourne et al (1975) Research in 10 Veterinary Science 18:244-248) The method of the present invention is performed on mammals. Preferably, the mammals used in the method are rodents or ruminants. Most preferably, the mammals are goats, sheep or cattle. Desirably the mammals are dairy cattle breeds; however dairy goat or sheep breeds may also be used. 15 The term "milk" used herein refers to both milk and colostrum in the form in which it is produced by the mammal or any derivative of whole milk, such as skimmed milk or whey, in liquid or in solid form. The term "antigen" as used herein refers to any material capable of inducing an antigenic response in a treated mammal. Antigens may be selected according to 20 the ultimate utility of the antibodies. That is, if the antibodies are to be used for generating passive immunity, the antigen against which such immunity is sought should be used may be derived from bacteria, viruses, yeasts, mycoplasmas, proteins, haptens, peptides, animal tissue extracts, plant tissue extracts, fungi, pollens, dust, chemical antigens intact mammalian cells (including spermatazoa) 25 and fractions of cells. Where haptens or peptides are to be used as antigens these should first be conjugated to carrier substances such as proteins using chemistry well known to people versed in the art (Hanly et al; Review of Polyclonal Antibody Production Procedures, ILAR Journal (1995), 37:3, 93-118).

WO 2006/037182 PCT/AU2005/001540 In one embodiment of the invention any bacterial antigen may be used in the invention. Preferably, the bacterial antigens are desirably selected from the bacterial species selected from, but no limited to: Escherichia, Staphylococcus, Streptococcus, Salmonella and Helicobacter. Particularly preferred bacterial 5 species are Escherichia coli, Clostridium difficile, Vibrio cholerae and Helicobacter pylori and Pseudomonas fluorescens. Most preferably, the antigen is lipoprotein lipase from Pseudomonas fluorescens. Implantation of the antigen releasing device adjacent to or within at least one supramammary lymph node causes the antigen contained in the antigen releasing 10 device to be released into the tissue near and within the node (Figure 1). This in turn stimulates the node to generate antibodies to the antigen. These antibodies are secreted into the mammary glands and therefore enter the milk of the mammal. The size, characteristics and choice of antigen releasing device is dependant on 15 the size and properties of the antigen of interest. It is desirable that the choice of antigen releasing device allows the antigen contained therein to be released from the device at a rate which causes the antibody response of the mammal into which it is implanted to be maintained at a desirable level. Devices for slow release of compositions are described in, for example, US Patent 20 No. 3,279,996, whilst immunopotentiating devices for the sustained release of antigen are described, for example, in Australian Patent No. 740133 A porous silicon implant impregnated with a beneficial substance is described in Patent No. DE69917625D. An implantable device for molecule delivery is described in U.S Patent No. 6,716,208.Other suitable examples of sustained 25 release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, e.g., films, or microcapsules compressed into delivery devices. Examples of sustained-release matrices include polyesters, hydrogels [e.g., poly(2 hydroxyethyl-methacrylate) as described by Langer et al., J. Biomed. Mater. Res. 30 15:167-277 (1981) and Langer, Chem. Tech. 12:98-105 (1982) or WO 2006/037182 PCT/AU2005/001540 -9 poly(vinylalcohol)], polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 [1983]), non-degradable ethylene-vinyl acetate (Langer et al., supra), degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM 5 (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Another reference is B.Baras, M.A. Benoit & J.Gillard (2000) "Parameters influencing the antigen release from spray dried poly (DL-lactide) microparticles." International Journal of Pharmaceutics, 200:133-145. 10 While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antigens remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 370C, resulting in a loss of biological activity and possible changes in immunogenicity. 15 Rational strategies can be devised for antibody stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular SS or disulfide bond formation through thio-disulfide interchange, stabilisation may be achieved by modifying sulfhydryl residues, lyophilising from acidic solutions, controlling moisture content, using appropriate 20 additives, and developing specific polymer matrix compositions. Sustained-release fragment compositions also include liposomally entrapped fragments. Liposomes containing the antibody are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Nat. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. NatI. Acad. Sci. USA 77:4030-4034 (1980); EP 25 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30% cholesterol, the selected proportion being adjusted for the optimal antibody therapy. Other devices for the 30 slow release of antigen into the tissue near the supramammary lymph node are encompassed within the present invention.

WO 2006/037182 PCT/AU2005/001540 -10 An effective amount of antigen to be employed therapeutically will depend, for example, upon the objectives, the route of administration, the type of antigen and/or adjuvant and the condition of the animal. Accordingly, it will be necessary for the therapist to titre the dosage and modify the mode of administration as 5 required to obtain the optimal effect. Typically, the operator will administer an antigen until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays. In the further aspect of the invention, there is provided a method for inducing the sustained release of antibodies in milk comprising the further step of administering 10 a primer composition by an administration route selected from intramammary, intraperitoneal, intramuscular or intranasal. Administration of a primer may take place before, during or after implanting the antigen releasing device. It is preferable that the primer composition be delivered to a mucosal surface so that antibody production on mucosal surfaces (of which the mammary gland is one) is 15 preferentially stimulated. The primer composition administration could be a single administration, or could comprise a number of administrations at intervals over a period of days or weeks. Timing of the administration of primer composition is generally spaced based on contemporary immunisation protocols (for example, every 2 weeks). To avoid 20 local irritation and congestion, it is usually preferred that the primer composition not be administered to the same site more frequently than every second week. The initial exposure of this priming step stimulates the low level production of antibodies, which production is then increased and maintained by antigen released by the antigen releasing device. 25 The method of the present invention may also comprise the additional step of administering a booster composition comprising antigen to a mammal by an administration route selected from intramammary, intraperitoneal, intramuscular and/or intranasal after the antigen releasing device has been implanted. It is preferable that the booster composition be delivered to a mucosal surface so that 30 antibody production on mucosal surfaces (of which the mammary gland is one) is preferentially stimulated.

WO 2006/037182 PCT/AU2005/001540 - 11 Such booster compositions could be administered as a single administration, or could comprise a number of administrations at intervals over a period of days or weeks. Administration of booster compositions is generally spaced to suit the convenience of the operator. To avoid local irritation and congestion, it is usually 5 preferred that administration of the booster composition to the same site not be more frequent than every other week. In a preferred method, the antigen administered is the same for each step of the method. Therefore, the same antigen may be used in the antigen releasing device, the primer composition and/or the booster composition. 10 The use of adjuvants both within the antigen releasing device and in the compositions used for priming and boosting is also desirable. An adjuvant can serve as a tissue depot that slowly releases the immunogen and also as a lymphoid system activator that non-specifically enhances the immune response [Hood et al., in Immunology, p. 384, Second Ed., Benjamin/Cummings, Menlo Park, California 15 (1984)]. Suitable adjuvants for use with the antigens of the invention include but are not limited to the following: Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIC), TiterMax Gold

TM

, adjuvant 65, cholera toxin B subunit, IL1-B Fragment 163-171 synthetic human adjuvant, alhydrogel; or bordetella pertussis, muramyl dipeptide, cytokines, saponin, Adju-Phos, Algal Glucau, 20 Algammuliu, Alhydrogel, Antigen Formulation, Avridine, Bay R1005, calcitrial, calcium phosphate, Gel, CRL 1005, cholera Holotoxin (CT), DDA, DHEA, DMPC, DMPG, DOC/Alum Complex, Gamma Inulin, Gerbu Adjuvant, GMDP, Imiquimod, Imuither, Interferon-gamma, ISCOM(s), Iscoprop 7.0.3, Loxoribine, LT-OA or LT Oral adjuvant, MF59, MONTANIDE ISA51 and ISA720, MPL, MTP-PE, MTP PE 25 Liposomas, murametide, murapalmitive, NAGO, Nonionic surfactant vesides, Pleuram, PLGA, PGA and PLA, Pluronic L121, PMMA, PODDS, Poly Ra, Polyru Polyphophazene, Polysorbate 80, Protein Cochleates, QS-21, Quil A, Rehydrogel HPA, Rehydrogel LV, S-28465, SAF-1, Sclavo, peptide, Seudai Protediposomes, sendai-contaiming lipid matrices, Span 85, specal, squalene, stearyl Tyrosine, 30 Theramide, Threonyl-MDP, Ty Particles, saponin 0521, MF59 and Alum.

WO 2006/037182 PCT/AU2005/001540 -12 In a further aspect of the invention, the method further comprises a preselection step. In this step individual animals are tested and selected for their ability to produce antibodies. Considerable between-animal variability exists for the production of antibodies. This preselection step, wherein the animals showing the 5 best antibody titre responses are selected, assists in decreasing the between animal variability factor. This process may similarly be used to build groups of animals particularly suited to antibody production. In relation to the step of administering the priming composition or the boosting composition, preferably the antigenic substances are suspended in liquid medium 10 for infusion or injection according to known protocols. Any appropriate carriers, diluents, buffers, and adjuvants known in the art may be used. Suitable suspension liquids include saline solution, water, and physiologic buffers. If administration of the priming composition or the boosting composition is by injection, preferably prior to injection the antigens are emulsified in appropriate 15 carriers with adjuvant using, for example, a laboratory homogeniser. In one example of such a method, aqueous antigen is mixed with 3 volumes of adjuvant and emulsified until a stable water-in-oil emulsion is formed. The presence of a stable emulsion can be demonstrated using tests well known in the art. According to a second aspect, the invention also provides antibodies produced by 20 any one of the methods of the present invention and fragments of such antibodies. The antibodies may be of any of the different subclasses or isotypes of immunoglobulin, eg IgA, IgG or IgM, or any of the other subclasses. Exemplary antibody molecules and fragments that may be prepared according to this aspect of the invention include intact immunoglobulin molecules, substantially 25 intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope. Such portion of antibodies that contain the paratope include those portions known in the art as Fab, Fab', F(ab') 2 and F(v). Fab and F(ab') 2 . These portions of antibodies may be prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by 30 methods that are well known. See for example, U.S. Pat. No. 4,342,566. Fab' WO 2006/037182 PCT/AU2005/001540 - 13 antibody portions are also well known and are produced from F(ab') 2 portions followed by reduction of the disulfide bonds linking the two heavy reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as 5 iodoacetamide. Preferably the antibodies are intact antibody molecules, and are utilised as illustrative herein. According to a third aspect the invention relates to a method for the production of mammalian milk containing antibodies, which method comprises induction of antibodies according to the method detailed above and then collecting the 10 antibody containing milk from the mammal. The collection of milk may be effected using normal milking processes. This milk is useful in the form obtained directly from the mammal, but may be processed if required. Examples of processing steps include heat treatment, ultra violet radiation, concentration, supplementation with food additives, drying into 15 concentrates, milk or whey powders and the like. As a further step to the method of the invention, the antibodies may be isolated from the milk. Isolation may be effected using separation techniques known in the art. For example, methods for the isolation of immunoglobulin rich fractions from whey (Nielson, K. (1986) Can. J. Vet. Res 50: 227-231; EP 0320152; WO 20 97/27757; GB2 179947) from milk (Kanamara et al (1993) Milchwissenschaft 48:247-251; U.S. Pat. No. 4,229,342), from colostrum (Kanamaru et al (1982) Agric. Biol. Chem 46:1531-1537, French Patent No. 2520235, New Zealand Patent No. 239466 and U.S. Pat. No. 4,582,580), and from milk and colostrum (U.S. Pat. No. 4,644,056) are known. 25 The isolated antibodies may subsequently be purified if desired. Purification may be carried out according to known techniques such as precipitation and ion exchange chromatography. Suitable techniques are disclosed in the journals and patents referenced above. Both the isolated and purified antibodies produced in accordance with the additional process steps also form part of the present 30 invention.

WO 2006/037182 PCT/AU2005/001540 -14 Methods for producing protein concentrates containing antibodies on a commercial scale are disclosed in Swiss Patent No. 1,573,995 incorporated herein by reference. Briefly, the method comprises collecting the milk of hyperimmunised milk-bearing females; separating the cream and the impurities, 5 coagulating the clarified and skimmed milk, separating the casein, filtering, ultrafiltering and sterilising the proteins of the whey by filtration, evaporating and drying the product under conditions which do not denature the antibodies and which maintain sterility. Examples 10 Further features of the present invention are more fully described in the following non-limiting examples. It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention. It should not be understood in any way as a restriction on the broad description of the invention as set out above. 15 Example 1 Preparation of Antigen Releasing Device minus adjuvant MATERIALS (i) 0.15g mannitol-D (Sigma-Aldrich) 20 (ii) 0.15g sodium citrate (Proanalys) (iii) 11.25mg lipase from Pseudomonas fluorescens (Sigma-Aldrich) (iv) 0.75 ml part A Silastic (Dow Corning Q7-4850) (v) 0.75 ml part B Silastic (Dow Corning Q7-4850) (vi) 2 x 2.5 ml disposable syringes (Terumo) 25 (vii) 2 x 1 ml syringe (Terumo) (viii) 2 x 12G x 4 inch stainless steel hypodermic needles (ix) 37 0C incubator (x) sterile petri dish (xi) sterile scalpel 30 (xii) sterile spachella WO 2006/037182 PCT/AU2005/001540 -15 (xiii) 32ml glass McCartney bottle METHODS (i) Remove pistons from all syringes 5 (ii) Part A silastic placed into 1 ml syringe using spatula. Piston replaced into syringe and 0.75ml quantity dispensed into one 2.5ml syringe. Procedure repeated for Part B. (iii) Lipase, mannitol and sodium citrate are combined and mixed in a small glass McCartney then placed into the 2.5ml syringe containing part A of the 10 silastic. Part B was then expelled from its syringe into the other 2.5ml syringe effectively 'sandwiching' the lipase, mannitol and sodium citrate between part A and part B of the silastic in one syringe. The piston was replaced in this syringe and removed from the empty syringe. The contents of the first syringe were expelled into the second syringe then its piston replaced. The procedure was 15 repeated 20 times to effectively mix all reagents. The reagents were finally expelled into two 12G needles and stored at 370C for three days. The cured silastic was extracted from the needles, cut into 3cm lengths in the open petri dish and placed under UV light for 24 hours before being stored in sterile 1 Oml centrifuge tubes at -20*C. Each 3cm ARD contained 1mg lipase, 13mg mannitol, 20 13mg sodium citrate, in 250 tl of total silastic. Example 2 Preparation of Antigen Releasing Device including adjuvant 25 MATERIALS (i) 0.3g mannitol-D (Sigma-Aldrich) (ii) 0.3g sodium citrate (Proanalys) (iii) 22.50mg lipase from Pseudomonas fluorescens (Sigma-Aldrich) (iv) 1.2mg IL1-B Fragment 163-171 synthetic human (Sigma) 30 (v) 1.5 ml part A Silastic (Dow Corning Q7-4850) (vi) 1.5 ml part B Silastic (Dow Corning Q7-4850) (vii) 2 x 2.5 ml disposable syringes (Terumo) WO 2006/037182 PCT/AU2005/001540 -16 (viii) 2 x 1 ml syringe (Terumo) (ix) 2 x 12G x 4 inch stainless steel hypodermic needles (x) 37 0C incubator (xi) sterile petri dish 5 (xii) sterile scalpel (xiii) sterile spachella (xiv) 32ml glass McCartney bottle METHODS 10 (i) Remove pistons from all syringes (ii) Part A silastic placed into 1 ml syringe using spatula. Piston replaced into syringe and 0.75ml quantity dispensed into one 2.5ml syringe. Procedure repeated for Part B. Lipase, mannitol and sodium citrate mixed in a small glass McCartney then 15 placed into the 2.5ml syringe containing part A of the silastic. Part B was then expelled from its syringe into the other 2.5ml syringe effectively 'sandwiching' the lipase, mannitol and sodium citrate between part A and part B of the silastic in one syringe. The piston was replaced in this syringe and removed from the empty syringe. The contents of the first syringe was expelled into the second syringe 20 then its piston replaced. The procedure was repeated 20 times to effectively mix all reagents. The reagents were finally expelled into two 12G needles and stored at 37 C for three days. The cured silastic was extracted from the needles, cut into 3cm lengths in the open petri dish and placed under UV light for 24 hours before being stored in sterile 1 0ml centrifuge tubes at -20 deg C. Each 3cm ARD 25 contained 1mg lipase, 13mg mannitol, 13mg sodium citrate, 50pg IL1-B, in 250pl of total silastic. Example 3 Delivery of ARD 30 A device was purpose designed and built comprising 1 Oml disposable luer lock syringe, 10G x 4 inch stainless steel hypodermic needle and a 90mm x 10G stainless steel welding rod (see Figure 5 below). The device was assembled with WO 2006/037182 PCT/AU2005/001540 -17 the rod attached to the piston of the syringe and passing through the needle. The piston was withdrawn about 3cm allowing for free space near the tip of the needle in which to insert the antigen releasing device. Thus, when the piston is depressed, the antigen releasing device is expelled from the needle by the rod 5 (see Figure 5 below). The animal was placed on the floor on its back and restrained by animal handlers. An area approximately 3cm x 10cm right lateral and adjacent to the udder was swabbed with iodine. 2ml of 2% lignocaine infiltrated the cutaneous tissue 10 through a 26G hypodermic needle as a local anaesthetic. The 1OG needle housing the ARD was inserted in the posterior end of this area and pushed to the anterior end subcutaneously. The piston was depressed and needle withdrawn simultaneously. The point of insertion was swabbed with iodine. In most cases the antigen releasing device could be felt in situ. 15 Example 4 Preparation of Lipase nasal indculum MATERIALS 20 (i) 15.5 mg lipase from P.fluorescens (Sigma-Aldrich) (ii) 38.75ml 0.85% saline (Excel laboratories) (iii) 1 mg Cholera Toxin B Subunit (US Biological) (iv) 2.5ml syringes (v) 50ml sterile tube (Falcon) 25 (vi) 8-10cm length of approximate 20G plastic tube from winged infusion set (Terumo) METHODS (i) All reagents were combined in 50ml tube on day of first administration. 30 (ii) The remainder was stored at 4 0 C until used.

WO 2006/037182 PCT/AU2005/001540 -18 Example 5 Delivery of Nasal Inoculum 2.5ml of inoculum (containing 1mg lipase, 64.5pg Cholera Toxin B Subunit) was 5 drawn into syringe with the 20G tube from the infusion set attached. 60-80% of tube length was placed into right nostril of animal and slowly dispensed whilst simultaneously withdrawing the tube from the nostril (see Figure 2). Example 6 Preparation of Lipase Intramuscular injected inoculum 10 MATERIALS (i) 36.5mg of lipase from P.fluorescens (Sigma) (ii) 9.1 ml of 0.85% saline (Excel Laboratories) (iii) TiterMax GoldTM adjuvant 15 (iv) glass McCartney bottle (v) 3ml all plastic syringes (Teruma) (vi) stainless steel double-hub (vii) 23G x 1 inch hypodermic needle 20 METHODS (i) Lipase and saline were combined in glass McCartney giving a concentration of 4mg/ml on the day of first administration. The remainder was stored at 4 0C until required. 25 Example 7 Delivery of Intramuscular Inoculum 0.5ml of 4mg/ml lipase in saline solution as drawn into syringe and emulsified with 0.5ml TiterMax GoldTM as per manufacturers instructions. Inoculum was 30 administered intramuscularly (IM) in the rear of the left hind leg using 23G x 1 inch WO 2006/037182 PCT/AU2005/001540 -19 needle attached to the syringe. Animals received IM injections Day 7, Day 14 and Day 21. Example 8 5 Immunisation Protocol 1 The animals were given an IM injection in the upper hind limb (rump). Five animals were immunised with four different antigens. Two animals each 10 received one type of antigen and the remaining three animals received a different antigen each. Table 1 summarises the schedule of the primary inoculums and two subsequent boosts, and the concentrations of antigen (Ag), and volumes of the TiterMax adjuvant (T/max). 15 WO 2006/037182 PCT/AU2005/001540 - 20 Table 1: Immunogen composition and inoculation schedule for goats inoculated with a variety of antigens. Goat inoculation Schedule PRIMARY INOCULATION Tag Antigen Primary Ag b.g) Ag(bl) T/Max(pi) Tot (pi) Bleed y/n X0247 P.f/uorescens lipase 28/11/2003 1250 250 750 1000 Y X0248 P.fluorescens lipase 28/11/2003 1250 250 750 1000 Y X0241 Type X protease 17/03/2004 500 500 500 1000 Y X0242 Type XVii-B protease 17/03/2004 500 500 500 1000 Y X0243 Type Vill protease 17/03/2004 500 500 500 1000 Y SECONDARY INOCULATION Tag Antigen S'dary Ag (pg) Ag(pl) T/M (pl) Tot (pl) Bleed y/n X0247 P.fluorescenslipase 10/12/2003 950 190 560 750 Y X0248 P.fluorescenslipase 10/12/2003 950 190 560 750 Y X0241 Type X protease 1/04/2004 500 500 500 1000 Y X0242 Type XVIli-B protease 1/04/2004 500 500 500 1000 Y X0243 Type Vill protease 1/04/2004 500 500 500 1000 Y TERTIARY INOCULATION Tag Antigen Tertiary Ag (pg) Ag(iI) T/M(pI) Tot (pL) Bleed y/n X0247 P.fluorescenslipase 22/12/2003 2500 500 500 1000 Y X0248 P.fluorescenslipase 22/12/2003 2500 500 500 1000 Y X0241 Type X protease 16/04/2004 500 500 500 1000 Y X0242 Type XVil-B protease 13/05/2004 500 500 500 1000 N X0243 Type VIII protease 16/04/2004 500 500 500 1000 Y WO 2006/037182 PCT/AU2005/001540 -21 Example 9 Immunization Protocol 2 5 The animals were given antigen inoculation by antigen releasing device (ARD) and/or injection. Table 2 summarises the schedule of inoculums and refers to 6 animals and one antigen. 10 One animal received a sub-cutaneous injection in the groin on Day 0 of the antigen and on Day 30 the same animal received an IM injection of the antigen. One animal received a sub-cutaneous injection of the antigen on Day 0 only. One animal received an implant having the antigen in the groin on Day 0. One animal 15 received an implant having the antigen in the groin on Day 0 and on Day 30 received an IM injection of the antigen in the rump. Two animals received an implant having antigen in the groin on Day 0 and on Day 15 one received a nasal and the other an IM injection boost.

WO 2006/037182 PCT/AU2005/001540 - 22 Table 2: Protocols for initial trial of antigen releasing device (ARD). Trial CRD and S/C injection of Ag to assess Ab secretion via mammary Date Tag Ag Amount Adjuvant Amount Delivery Total Vol Location Milk y/n Bleed y/n 28/04/2004 White 651 8RS Lipase 2.5 mg T/Max 500ul S/C 1ml groin Y Y 28104/2004 Black 1292 BX8 Lipase 2.5 mg T/Max 500ul S/C imi groin Y Y 28/04/2004 Black 1675 BX8 Upase 250ug unsheathed silastic CRD S/C RH groin Y Y 28/04/2004 White 552 8RS Lpase 250ug sheathed silastic CRD IS/C I IRH groin Y Y Date Tag Ag Amount Adjuvant Amount Delivery Total Vol Location Milk y/n Bleed y/n 13/05/2004 White 651 8RS Lipase 0 0 0 0 0 0 Y Y 13/05/2004 Black 1292 BX8 ILpase 0 0 0 0 0 0 Y Y 13/05/2004 Black 1675 BX8 Lipase CRD Y Y 13/05/2004 White 552 8RS Upase CRD Y Y 13/05/2004 White 367 lipase 1mg / 12mg mannitol/12mg SC-CRD 30x2mm Rh groin Y Y 13/05/2004 Orange 468 lipase 1mg / 12mg mannitol/1 2mg SC-CRD 30x2mm Rh groin Y Y Date Tag Ag Amount Adjuvant Amount Delivery Total Vol Location Milk y/n Bleed y/n 28/05/2004 White 651 8RS Lipase 2.5 mg T/Max 500ul S/C | 1ml RH rump Y Y 28/05/2004 Black 1292 BX8 Lipase 0 0 0 0 0 0 Y Y 28/05/2004 Black 1675 BX8 Lipase 0 0 0 0 0 0 Y Y 28/05/2004 White 552 8RS Upase 2.5 mg T/Max 500ul S/C 1 ml RH rump Y Y 28/05/2004 White 367 lipase 2.5 mg in 2.5 ml saline 2.5ml nasal Y Y 28/05/2004 Orange 468 lipase 2,5 mg T/Max 500ul S/C 1ml Lhrump Y Y Date Tag Ag Milk y/n I Bleed y/n 1 1/07/2004 White 367 lipase Y Y 1/07/2004 Orange 468 llpase Example 10 Immunisation protocol 3 5 Protocols used 2 animals per group with 12 goats used in total. Six different protocols were evaluated in two separate animals to determine an optimal procedure to produce sustained antibody levels in milk, summarised in 10 Table 4 and 5.

WO 2006/037182 PCT/AU2005/001540 - 23 Table 4: The immunisation protocols used to stimulate the production of antibodies in milk. Innoculatio Protocol Sampling Frequency Group Description Adjuvant Day 1 Day 7 Day 14 Day21 Collec ion Collection 1 Intramuscular (IM) YES IM injection IM boost IM injection Daily 34 day injection only intervals 2 ARD only YES Implant ARD Daily ay 3 Intranasal (IN) spray YES IN innoculat IN boost IN boost Daily 3-4 day only intervals 4 Intramuscular (IM) YES Implant ARD Daily 3-4 day injection + ARD intervals 5 Intranas (IN) spriay + YES IM injection IM boost IM injection Daily 3-4 day ARD intervals 6 ARD only NO Implant ARD Daily inteay 5 WO 2006/037182 PCT/AU2005/001540 - 24 Table 5: The immunisation protocols used to stimulate the production of antibodies in milk. Group 1- inject S/Mark Inoculum Amount Delivery Site Freq lipase 2.0mg 1.M R/h quart Day 7 TiterMax 500ul Day 14 saline 50001 Day2l Group 2 - CRD'lnc Adj S/Mark Inoculum Amount Delivery Site Freq lipase 1mg CRD RH groin Day 0 mannitol 13mg sod citrate 13mg IL-1B 50ug silastic 250ul Group 3- nasal only S/Mark Inoculum Amount Delivery Site Freq lipase 1mg nasal nostril Day 7 C/ Tox Day 14 saline 2.5m] Day 21 Group 4 -CRD & inj S/Mark Inoculum Amount Delivery Site Freq lipase 1mg CRD RH groin Day 0 mannitol 13mg sod citrate 13mg IL-1B 50ug silastic 250ul lipase 2.0mg 1.M R/h quart Day 7 TiterMax 500ul Day 14 saline 500ul Day 21 S/Ou p RIcRD & nasal S/Mark Inoculum Amount Delivery Site Freq lipase 1mg CRD RH groin Day 0 mannitol 13mg sod citrate 13mg IL-1B 50ug silastic 250ul lipase 1mg nasal nostril Day 7 C/ Tox Day 14 saline 2.5ml Day 21 Group 6 - CRD minus Adi S/Mark Inoculum Amount Delivery Site Freq lipase 1mg GRD RH groin Day 0 mannitol 13mg sod citrate 13mg silastic 250ul 5 WO 2006/037182 PCT/AU2005/001540 - 25 A total of 12 goats were studied, with two goats dedicated to each inoculation regime. The presence of anti-lipase antibodies was evaluated with Enzyme Linked Immunosorbent Assay (ELISA). The mean absorbance value less that of the blank control of the daily milk samples were plotted (Figure 6). Results were 5 reproducible between animals, as shown in Figure 7. All six regimens were successful in raising antibodies. However, the relative concentrations of antibodies for each group varied. The highest mean absorbance value; which is indicative of the greatest concentration of antibodies 10 produced; was recorded for the Group 4 animals. The Group 4 animals received an ARD implant on Day 0 of the program and 3 subsequent injections to the back flank area on Days 7, 14 and 21. The mean absorbance value of Group 4 was greater than the value produced by 15 the Group 1 goats, who only received IM injections at day 7, 14 and 21. Both Group 1 and 4 animals showed some response up to approximately Day 14. At Day 15, the levels of anti-lipase antibodies increased substantially, presumably a consequence of the secondary immune response. The higher levels of 20 antibodies were sustained for the duration of the study, in this case up to Day 28. The levels of anti-lipase antibodies in the serum of the inoculated animals was also measured, as shown in Figures 8, 9 and 10. Figure 8 shows results of the individual absorbance levels of anti-lipase antibodies in two separate animals 25 implanted with an antigen releasing device (ARD) and given intramuscular injections. Figure 9 shows results of the level of anti-lipase antibodies in serum from goats immunised with different protocols. Figure 10 shows results of a comparison of mean anti-lipase anti-body levels in milk and serum produced by immunisation of goats with an antigen releasing device (ARD) and intramuscular 30 injection. Figure 11 shows the anti-lipase antibody production in milk and serum in goats implanted with an antigen releasing devices. The level of anti-lipase antibody levels in milk and the absence of anti-lipase antibodies in serum suggest WO 2006/037182 PCT/AU2005/001540 - 26 that the antigens in the antigen releasing device implanted in the groin area are diffusing into the supramammary lymph node. Example 11 Immunization Protocol 4 5 The protocol used two lactating goats (Capra hircus) for each group, with four goats used in total. The antigen used was lipase from Pseudomonas fluorescens. - Preparation for immunisation protocol 1. Emulsify 30mg of lipase in 15ml 0.85% saline. 2. Emulsification with Titermax Gold was according to manufacturer's 10 specification. The lipase in saline solution was mixed with an equal volume of Titremax Gold (1:1). 3. Dispense 1 ml into 2.5ml syringe for administraton. (Each 1 ml dose contains 1 mg lipase) 4. Two groups of animals were inoculated on Day 0, 10 and 19. 15 5. Group 1 was inoculated in the left flank and Group 2 was inoculated adjacent to the supramammary lymph node. 6. Milk and serum was collected. - Coating plates for Enzyme Linked Immunosorbent Assay (ELISA) 1. Prepare 2.5 tg/ml of antigen in coating buffer. 20 2. 1 00sl of the mixture was dispensed into each well of a 96 well ELISA tray. 3. The plates were covered and were left to stand overnight at 4 0 C. - Enzyme Linked Immunosorbent Assay (ELISA) protocol 1. Prior to use, the coated plates were washed 3 times with PBS Tween. 2. A serum diluent of 1% Human serum in PBS Tween. 25 3. Load 100pl of the serum diluent into each well. 4. Load 1 Id of sample of interest to well. 5. Plates were incubated at 370C for 2 hours.

WO 2006/037182 PCT/AU2005/001540 - 27 6. Plates were washed 3 times with PBS Tween. 7. 1/1000 dilutions of mouse a-sheep IgG, mouse a-sheep IgA and mouse a sheep IgM in 1% serum diluent (1% Human serum in PBS Tween) were prepared. 5 8. Load 1 00 I into respective wells. 9. The plates were placed in 370C for 2hrs. 10. The plates were washed 3 times with PBS Tween. 11. 1/2500 dilution of rabbit a-mouse IgG (H+L) in 1% serum diluent was prepared. 10 12. Load 1 00 I per well. 13. Incubate at 370C for 2hrs. 14. The plates were washed 3 times with PBS Tween. 15. A 1/100 dilution of 250mg/ml Nitrophenyl phosphate in Diethanolamine Buffer was prepared. 15 16. Load 1 00 I per well. 17. Incubate at room temperature for approximately 20 to 30 minutes. 18. The reaction was terminated with 50ul of 3.75M NaOH. 19. ELISA plates were read at 405nm. 0 Results 20 Milk collected was analysed by ELISA for levels of IgG, IgA and IgM. Results from Group 1 (intermuscular into the flank - designated G1) and Group 2 (stimulation of the supramammary lymph node - G2 animals) in Figure 13 shows higher levels of all three classes of immunoglobulin produced in the milk of Group 2 animals when compared to Group 1 animals. 25 Example 12 Collection and storage of milk samples MATERIALS (i) Beckman Acuspin refridgerated centrifuge WO 2006/037182 PCT/AU2005/001540 - 28 (ii) Rennet Type Il from Mucor meihei (Sigma) in Hp water at a concentration of 2mg/ml (ii) 1 Oml sterile centrifuge tubes (iv) P1000 pipetteman 5 (v) 1 ml disposable transfer pipettes (vi) 5ml plastic storage tubes (vii) 370C incubator METHOD 10 Milk was collected by hand milking into 32ml glass McCartney bottles in the absence of any chemical or mechanical stimuli. Milk was generally collected in the morning without prior separation from kids. Samples were stored on ice after collection and transferred as soon as practicable thereafter. Milk was transferred to sterile 10ml centrifuge tubes and centrifuged at 2000rpm for 15mins at 40C. 15 Milk was aspirated from under the solid fat layer using disposable pipette and placed in fresh 1 Oml tube. The pipette was carefully plunged through the fat layer into the milk layer below. 2mg/ml Rennet solution was added to the milk at the ratio of 0.4ml rennet to 5ml milk, tubes were shaken then incubated at 370C for 1 to 2 hours. Tubes were centrifuged at 5000rpm x 15mins at 40C. Supernatant 20 was removed by transfer pipette and stored at -20*C. Antibodies in the milk were quantified by the Enzyme-Linked Immunisorbent Assay (ELISA). The absorbance values, which are indicative of relative concentrations of the anti-lipase antibody, for serum were lower when compared 25 to milk. The levels of anti-lipase antibodies produced in the milk were higher when compared to antibody levels in serum. Example 13 Collection and storage of blood samples 30 MATERIALS (i) 7ml of 9ml VacutainerTM (Bectco Dickinson) for serum collection (ii) 20G x 1.5inch VacutainerTM (Bectco Dickinson) needles and holder WO 2006/037182 PCT/AU2005/001540 - 29 METHODS Blood samples were taken from the jugular vein using VacutainerTM collection tubes, holder and needle. Tubes were stored at 40C. Samples were centrifuged 5 at 4000rpm x 15min at 40C. Upper serum layer was removed using a transfer pipette and stored at -20 0C. Example 14 Enzyme-Linked Immunosorbent Assay (ELISA) 10 MATERIALS (i) 10 x Phosphate Buffer Saline (PBS); 1 L double distilled water, 1.91 g

KH

2

PO

4 (BDH Chemicals Aust Pty Ltd), 6.1 g Na 2

HPO

4 (ASAX Chemicals), 2g KCI (BDH Chemicals Aust Pty Ltd), (ii) 80g NaCl, 1.95g NaN 3 (Sigma Aldrich), pH to 7.4 15 (iii) 200ml Carbonate coating buffer pH 9.6 containing; 200ml double distilled water, 3.18g Na 2

CO

3 (BDH), 5.88g NaHCO 3 (BDH), 0.39g NaN 3 (Sigma). (iv) 0.85% saline (Excel Laboratories) (v) 0.25 mg/ml lipase from P.fluorescens (Sigma Aldrich) in carbonate coating buffer 20 (vi) PBS-TW20 plate washing solution (BDH); 200ml 10 x PBS (as above), 1800ml distilled water, 1 ml Tween-20 (Labchem) (vii) Serum diluent; 200ml glycerol (BDH), 29g NaCl (BDH), 0.2g KH 2

PO

4 (BDH), 0.61g Na 2

HPO

4 (BDH), 0.2g KCI (BDH), 1.95g NaN 3 (Sigma), distilled water to 1 L, 1.5ml Tween-20 (Labchem), pH to 7.4. Store 4 0 C. 25 Dessicated BSA (CSL) added to desired aliquot at 1% concentration, prior to use. (viii) Saline 0.85% (Excel Laboratories) (ix) Donkey anti-goat IgG-Horse Radish Peroxidase (HRP) (Promega) (x) 1 M H 2 SO4 (AJAX Finechem) 30 (xi) TMBS EIA solution (BioRad) Part A & B (xii) P200 pipetteman and tips (xiii) P20 pipetteman and tips (xiv) nuncTM polsorb 96 well ELISA plates WO 2006/037182 PCT/AU2005/001540 - 30 (xv) BioRadTM 96 well plate spectrophotometer model 450 METHODS 100AI of lipase in carbonate buffer added to wells of ELISA plate and stored at 5 40C overnight. Plates were washed 3 times with PBS-TW. 1 00pl of serum diluent was added to wells for serum analysis, and 90RI were added to wells for milk analysis. 1 Itl of serum sample and 1 I~tl of milk sample added to the serum diluent. The mixture was created by gentle tapping the plate. The plates were stored at 40C overnight. The plates were washed 3 times with PBS-TW. 1 00LI of 10 a 1/2500 dilution of Donkey anti-goat IgG-HRP in 0.85% saline added to each well. The plates were incubated at room temperature for 1 hour. The plates were washed 3 times with PBS-TW. 9 Part A and 1 part B of TMBS were mixed in a glass Schott bottle and 100 I was added to each well. The plates were incubated at room temperature for 10 minutes. 1 00 d 1 M H 2

SO

4 was added to each well 15 and plate read on spectrophotometer at 450nm. A printout of the absorbance results was obtained. The absorbance values of each milk and blood sample collected from all animals were measured. Plots of absorbance values on the y axis against time (days) on the x-axis were prepared for individual animals and the average absorbance value for each group (comprising two test subjects). 20 Example 15 Lipase diffusion in milk agar slide (i) Prepare 1% (1g/100ml) agar (Oxoid Cat No L13, Basingstoke, Hampshire, 25 England) in Phosphate Buffer Saline (pH 7.4). (ii) Add 1 00[d of whole milk (Masters, Perth, Australia) to 5ml 1 % agar. (iii) For slide format, 2.5ml of 'milk agar' is poured over the glass and allowed to set for 10 minutes (2% milk in 1% agar). (iv) Five 1.5mm diameter holes in the milk agar gel were prepared with an agar 30 punch and the agar removed by vacuum. (v) The agar film was incubated over night with lipase from P. fluorescens (Aldrich, Milwaukee, WI, USA). 5mg/ml of lipase was prepared in 0.85% saline.

WO 2006/037182 PCT/AU2005/001540 - 31 (vi) The diffusion zone, indicative of lipid degradation of the lipase test was compared to plate with (a) saline, (b) lipase + antibody negative serum and (c) lipase + anti-lipase positive serum. 5 Results are present in Figure 11. On each milk slide, 5 wells were filled with saline (slide 1), the lipase enzyme (slide 2), lipase with an antibody negative serum (slide 3) and lipase with an anti-lipase antibody positive serum (slide 4). In slide 2, a zone of hydrolysis is visible as the lipase enzyme hydrolyses the lipids in the milk film. The negative control (saline in slide 1) confirms that the enzyme is 10 responsible for the zone of hydrolysis. The hydrolysis activity of the lipase enzyme can be inhibited by an anti-lipase antibody, as evident in slide 4. Slide 3 which contains an antibody negative serum confirms that it is the antibody and not other components of serum that is inhibiting the enzyme. 15 Although the invention has been described with reference to certain preferred embodiments, it will be appreciated that many variations and modifications may be made within the scope of the broad principles of the invention. Hence, it is intended that the preferred embodiments and all of such variations and modifications be included within the scope and spirit of the invention. 20

Claims (23)

1. A method for inducing the sustained release of antibodies in milk comprising the steps of: a) administering a primer composition; 5 b) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, and c) administering a booster composition comprising antigen to a mammal after the antigen releasing device has been implanted wherein in use the antigen releasing device releases an antigen into the tissue 10 area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

2. The method of claim 1 wherein the implant is located in sufficient proximity to the supramammary gland such that the release of antigen from the antigen releasing device induces the production of antibodies in milk over the life of the 15 antigen releasing device.

3. The method of claim 2 wherein the antigen releasing device is implanted at a distance of up to 100 mm from at least one supramammary lymph node.

4. The method of claim 3 wherein the antigen releasing device is implanted at a distance of between about 1 mm and 100 mm from at least one 20 supramammary lymph node.

5. The method of claim 4 wherein the antigen releasing device is implanted at a distance of between about 50 mm and 100 mm from at least one supramammary lymph node. - 33

6. The method of any one of claims 1-5 wherein the antigen releasing device is implanted in a mammal selected from the group comprising: goats, sheep and cattle.

7. The method of any of the above claims wherein the antigen is a bacterial 5 antigen.

8. The method of claim 7 wherein the bacterial antigen is from a bacterial genus selected from: Escherichia, Staphylococcus, Streptococcus, Salmonella and Helicobacter.

9. The method of claim 7 wherein the bacterial antigen is lipoprotein lipase from 10 Pseudomonas fluorescens.

10. The method of claim 1 wherein the antigen releasing device allows the antigen contained therein to be released from the device at a rate which causes the antibody response of the mammal into which it is implanted to be maintained at a desirable level. 15

11. The method of claim 1 wherein the primer or the booster is administered by an administration route selected from: intramammary, intraperitoneal, intramuscular or intranasal.

12. The method of claim 1 wherein administration of the primer takes place before implanting the antigen releasing device. 20

13. The method of claim 1 wherein administration of a primer takes place during implantation of the antigen releasing device.

14.The method of claim where the primer composition or the booster composition is delivered to a mucosal surface.

15.The method of claim 1 wherein the primer composition is administered in a 25 single administration. -34

16.The method of claim 1 wherein the primer composition is administered in a number of administrations at intervals over a period of days or weeks.

17.The method of claim 1 wherein the booster composition is administered in a single administration. 5

18.The method of claim 1 wherein the booster composition is administered in a number of administrations at intervals over a period of days or weeks.

19.The method of any one of claims 1 to 18 wherein the antigen administered is the same for each step of the method.

20.A method according to any one of claims 1 to 19 further comprising a 10 preselection step prior to administration of the antigen releasing device wherein animals showing the best antibody titre responses are used in the methods of any one of claims 1 to 21.

21.A method according to any one of claims 1 to 20 comprising the further step of: 15 a) collecting the antibody containing milk from the mammal.

22.The method of claim 21 comprising the further step of isolating the antibodies from the milk.

23.A method for producing protein concentrates containing antibodies comprising the steps of: 20 a) collecting the milk of milk-bearing female mammals implanted with antigen releasing device according to the method of any one of claims 1 to 20; b) separating the cream and the impurities; c) coagulating the clarified and skimmed milk; - 35 d) separating the casein; e) filtering, ultrafiltering and sterilising the proteins of the whey; f) evaporating and drying the proteins under conditions which do not denature the antibodies and which maintain sterility. 5